VYNE
Income statement / Annual
Last year (2025), VYNE Therapeutics Inc's total revenue was $570.00 K,
an increase of 13.77% from the previous year.
In 2025, VYNE Therapeutics Inc's net income was -$26.48 M.
See VYNE Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$570.00 K |
$501.00 K |
$424.00 K |
$477.00 K |
$931.00 K |
$20.99 M |
$443.00 K |
$10.64 M |
$4.58 M |
$674.00 K |
| Cost of Revenue |
$23.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.39 M
|
$350.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$547.00 K
|
$501.00 K
|
$424.00 K
|
$477.00 K
|
$931.00 K
|
$19.60 M
|
$93.00 K
|
$10.64 M
|
$4.58 M
|
$674.00 K
|
| Gross Profit Ratio |
0.96
|
1
|
1
|
1
|
1
|
0.93
|
0.21
|
1
|
1
|
1
|
| Research and Development Expenses |
$19.24 M
|
$30.95 M
|
$16.31 M
|
$18.39 M
|
$19.54 M
|
$43.53 M
|
$53.76 M
|
$52.99 M
|
$29.01 M
|
$11.26 M
|
| General & Administrative Expenses |
$11.08 M
|
$13.19 M
|
$13.38 M
|
$16.39 M
|
$0.00
|
$0.00
|
$22.48 M
|
$12.19 M
|
$5.17 M
|
$3.75 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.08 M
|
$13.19 M
|
$13.38 M
|
$16.39 M
|
$20.30 M
|
$89.54 M
|
$22.48 M
|
$12.19 M
|
$5.17 M
|
$3.75 M
|
| Other Expenses |
-$23.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$366.02 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$30.30 M
|
$44.14 M
|
$29.68 M
|
$34.77 M
|
$39.84 M
|
-$232.95 M
|
$76.24 M
|
$65.18 M
|
$34.18 M
|
$15.01 M
|
| Cost And Expenses |
$30.32 M
|
$44.14 M
|
$29.68 M
|
$34.77 M
|
$39.84 M
|
-$231.55 M
|
$76.24 M
|
$65.18 M
|
$34.18 M
|
$15.01 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.09 M
|
$517.00 K
|
$264.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.61 M
|
$4.39 M
|
$921.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$4.00 K
|
$0.00
|
$72.00 K
|
$109.00 K
|
$341.00 K
|
$350.00 K
|
$22.00 K
|
$8.00 K
|
$4.00 K
|
| EBITDA |
-$26.73 M |
-$43.63 M |
-$29.26 M |
-$34.22 M |
-$38.80 M |
-$251.10 M |
-$94.08 M |
-$54.54 M |
-$29.59 M |
-$14.33 M |
| EBITDA Ratio |
-46.9
|
-87.09
|
-69
|
-71.75
|
-41.68
|
-11.96
|
-212.38
|
-5.13
|
-6.46
|
-21.26
|
| Operating Income Ratio |
-52.19
|
-87.1
|
-69
|
-71.9
|
-41.79
|
12.03
|
-172.1
|
-5.13
|
-6.46
|
-21.26
|
| Total Other Income/Expenses Net |
$3.02 M
|
$3.83 M
|
$1.39 M
|
$363.00 K
|
-$4.85 M
|
-$508.37 M
|
-$19.11 M
|
$3.09 M
|
$517.00 K
|
$264.00 K
|
| Income Before Tax |
-$26.73 M
|
-$39.80 M
|
-$27.87 M
|
-$33.93 M
|
-$43.76 M
|
-$255.83 M
|
-$73.70 M
|
-$51.45 M
|
-$29.08 M
|
-$14.07 M
|
| Income Before Tax Ratio |
-46.9
|
-79.45
|
-65.74
|
-71.14
|
-47
|
-12.19
|
-166.37
|
-4.84
|
-6.35
|
-20.87
|
| Income Tax Expense |
$4.00 K
|
$4.00 K
|
$0.00
|
$13.00 K
|
$448.00 K
|
-$258.00 K
|
-$3.24 M
|
$0.00
|
-$8.00 K
|
$0.00
|
| Net Income |
-$26.48 M
|
-$39.83 M
|
-$28.45 M
|
-$23.21 M
|
-$73.33 M
|
-$255.57 M
|
-$70.46 M
|
-$51.45 M
|
-$29.08 M
|
-$14.07 M
|
| Net Income Ratio |
-46.46
|
-79.51
|
-67.1
|
-48.66
|
-78.76
|
-12.17
|
-159.06
|
-4.84
|
-6.35
|
-20.87
|
| EPS |
-0.62 |
-0.94 |
-2.77 |
-10.65 |
-25.65 |
-141.9 |
-149.48 |
-170.94 |
-101.65 |
-46.49 |
| EPS Diluted |
-0.62 |
-0.94 |
-2.77 |
-10.65 |
-25.65 |
-141.9 |
-149.48 |
-170.94 |
-101.65 |
-46.49 |
| Weighted Average Shares Out |
$42.77 M
|
$42.59 M
|
$10.27 M
|
$3.19 M
|
$2.86 M
|
$1.80 M
|
$471.39 K
|
$300.95 K
|
$286.04 K
|
$302.59 K
|
| Weighted Average Shares Out Diluted |
$42.77 M
|
$42.59 M
|
$10.27 M
|
$3.19 M
|
$2.86 M
|
$1.80 M
|
$471.39 K
|
$300.95 K
|
$286.04 K
|
$302.59 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
